Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

August 23, 2022

Study Completion Date

April 25, 2023

Conditions
Epilepsy
Interventions
DRUG

perampanel

oral suspension.

Trial Locations (18)

19104

Children's Hospital of Philadelphia, Philadelphia

27157

Atrium Health Wake Forest Baptist Medical Center PPDS, Winston-Salem

27710

Duke University Medical Center, Children's Health Center, Durham

30329

Children's Healthcare of Atlanta, Atlanta

30912

Augusta University, Augusta

32561

NW FL Clinical Research Group, LL-ClinEdge- PPDS, Gulf Breeze

32819

Pediatric Neurology PA, Orlando

33470

Axcess Medical Research, Loxahatchee Groves

33609

Pediatric Epilepsy And Neurology Specialists, Tampa

61801

Carle Foundation Hospital, Urbana

78249

Road Runner Research, Ltd, San Antonio

78749

Child Neurology Consultants of Austin, Austin

90027

Children's Hospital Los Angeles, Los Angeles

90095-1752

David Geffen School of Medicine at UCLA, Los Angeles

40536-0284

University of Kentucky, Lexington

64108-4619

Children's Mercy Hospital, Kansas City

08901

Children's Hospital at Saint Peter's University Hospital, New Brunswick

LV-1004

Children's Clinical University Hospital, Riga

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02914314 - Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy | Biotech Hunter | Biotech Hunter